It has been reportedly said that Nicholas Piramal India Ltd which imports the raw material and manufactures Madopar, Parkinson’s drug, locally has ceased its production in both vial and tablet form following price control.
The company had approached the National Pharmaceutical Pricing Authority (NPPA) to reconsider its price revision. However, according to NPPA sources the cased was already ‘‘pending review’’ with the Ministry of Chemicals and Fertilisers.According to NPPA sources the 10 tablet strips came under the price control which the company launched after the price control on vials. The existing MRP of a 10 tablet strip of 250 mg was Rs 56, whereas the company was seeking an MRP of Rs 97.84 to make it viable for the company.
